the first-line treatment of advanced non-small cell lung cancer.
-- In September, the U.S. Food and Drug Administration approved a new,
pre-filled insulin pen, KwikPen(TM), which will be available with any
of the Humalog formulations. Launch is expected in early 2008.
-- In October, the United States Supreme Court denied the petitions for
certiorari that were filed by Teva Pharmaceuticals and Dr. Reddy's
Laboratories regarding their challenges to the validity of Lilly's U.S.
-- In October, as a part of ongoing discussions with the U.S. Food and
Drug Administration, the company updated the Zyprexa (olanzapine) and
Symbyax (olanzapine and fluoxetine HCl) U.S. product labels.
Specifically, the changes include new warnings for weight gain and
hyperlipidemia (elevation of triglycerides and cholesterol) and updated
information in the warning for hyperglycemia (elevated blood sugar).
The label also states that while relative risk estimates are
inconsistent, the association between atypical antipsychotics and
increases in glucose levels appears to fall on a continuum and
olanzapine appears to have a greater association than some other
"Lilly continued to deliver excellent financial results to our shareholders in the third quarter, and we remain on pace for a very solid year," commented Sidney Taurel, chairman and chief executive officer. "Our ongoing focus on volume-based revenue growth and cost containment again allowed us to leverage double-digit sales growth into robust earnings per share results for the quarter on a pro forma adjusted basis."
Third-Quarter Reported Results
Worldwide reported sales for the quarter were $4.587 billion, an
increase of 19 percent compared with the third quarter of 2006. Worldwide
sales volume increased 14 percent,
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved